Genaissance Moves into Nutrigenomics with Sciona Licensing Deal | GenomeWeb

NEW YORK, Nov. 18 (GenomeWeb News) - Genaissance Pharmaceuticals today announced that it has licensed its HAP genotyping technology platform to consumer product biotech firm Sciona.

In exchange for the technology license, Genaissance obtained a 30 percent equity position in the privately traded UK-based company. Genaissance will receive royalties on any products Sciona develops using the HAP technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.